USFDA concludes inspection at Marksans Pharma Goa facility with zero Form 483 observation

Day 1 conference highlights include news from Moderna, BridgeBio

DRRA1 day ago 0

FDA again rejects tabelecleucel for EBV-driven post-transplant lymphoproliferative disease

DRRA1 day ago 0

New data, nuances in managing resistant gram-negative infections

DRRA1 day ago 0

New Year’s resolutions 2026: Lessons from colleagues

DRRA1 day ago 0